Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Thrombolysis in myocardial infarction

Thrombolysis in Myocardial Infarction (TIMI) Grade Flows... [Pg.217]

Features identifying low-, moderate-, and high-risk NSTE ACS patients are described using the thrombolysis in myocardial infarction (TIMI) risk score in Table 5-1.13... [Pg.90]

Antman EM, Giugliano RR Gibson MC, etal., forthe TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis result of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999 99 2720. [Pg.56]

Sabatine MS, McCabe CH, Gibson CM, Cannon CP Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28trial. Am HeartJ 2005 149 227-233. [Pg.67]

Antman EM, McCabe CH, Gurfinkel ER et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) I I B trial. Circulation 1999 100 1593-1601. [Pg.84]

Abbreviations AMI, acute myocardial infarction ARGAMI, argatroban in acute myocardial infarction MINT, myocardial infarction with novastan and tissue plasminogen activator SK, streptokinase TIMI, thrombolysis in myocardial infarction tPA, tissue plasminogen activator, UFH, unfractionated heparin. [Pg.99]

Cannon CR McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction results of the thrombolysis in myocardial infarction (TIMI) 5 trial, J Am Coll Cardiol 1994 23 993-1003. [Pg.106]

Scharfstein JS, Abendschein DR, Eisenberg PR, et al. Usefulness offibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in myocardial infarction. Am J Cardiol 1996 78 503-510. [Pg.125]

Diminishment after Acute Myocardial Infarction (FLORIDA) (22), Pravastatin in Acute Coronary Treatment (PACT) (23), Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 (PROVE-IT TIMI 22) (24), and A to Z (25) studies. [Pg.158]

Abbreviations ACS. acute coronary syndrome AECG. ambulatory electrocardiogram FLORIDA, fluvastatin on risk diminishment after acute myocardial infarction Ml. myocardial infarction MIRACL, myocardial ischemia reduction with aggressive cholesterol lowering nfMI. nonfatal myocardial infarction PACT, pravastatin in acute coronary treatment PROVE-IT TIMI 22. pravastatin or atoivastatin evaluation and infection therapy—thrombolysis in myocardial infarction 22 UAP, unstable anginapectoris. [Pg.161]

There is evidence that coronary blood flow is improved in patients pretreated with statins after acute infarct PCI (73,74). Celik et al, (74) found that Thrombolysis In Myocardial Infarction (TIMI) frame counts were lower, implying better coronary blood flow, in patients who underwent successful acute infarct PCI and were taking atorvastatin for >6 months compared to patients not taking statins. Iwakura et al. found a lower incidence of coronary no-reflow in patients on chronic statin therapy compared to those not taking statin after successful Ml (9,1 % vs. 34% P = 0.003). Multivariate analysis indicated that statin pretreatment was a protective factor against no-reflow. In this study, the statin-treated patients also had better wall motion, smaller left ventricular dimensions and ejection fraction (73). These studies suggest that statin therapy may help to preserve coronary microvascular function in the setting of acute infarct PCI. [Pg.165]

Cannon CR Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med 2004 350 1495-1 504. [Pg.520]

Sabatine MS, Cannon CR Gibson CM. Clopidogrel as adjunctive reperfusion therapy (CLARITY)-thrombolysis in myocardial infarction (TIM I) 28 investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics the PCI-CLARITY study. JAMA 2005 294(10) 1224-1232. [Pg.534]

Gore JM, Sloan M, Price TR, Randall AM, Bovill E, Collen D, Forman S, Knatterud GL, Sopko G, Terrin ML. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, phase 11, pilot and clinical trial. Circulation 1991 83(2) 448-59. [Pg.3407]

N. A. Ruocco, B. A. Bergelson, A. K. Jacobs, M. M. Frederick, D. P. Faxon, T. J. Ryan, Invasive versus conservative strategy after thrombolytic therapy for acute myocardial infarction in patients with antecedent angina. A report from Thrombolysis in Myocardial Infarction phase II study (TIMI II), J Am Coll Cardiol 20,1445—1551 (1992). [Pg.185]

Figure 8.38 (A) Relationship between Thrombolysis in Myocardial Infarction (TIMI) risk index and mortality in non-ST-segment myocardial infarction (NSTE-ACS). (B) Relationship between TIMI risk index and mortality in... Figure 8.38 (A) Relationship between Thrombolysis in Myocardial Infarction (TIMI) risk index and mortality in non-ST-segment myocardial infarction (NSTE-ACS). (B) Relationship between TIMI risk index and mortality in...
Wiviott SD, Morrow DA, Frederick PD, Antman EM, Braun-wald E National Registry of Myocardial Infarction. Application of the thrombolysis in myocardial infarction risk index in non-ST-segment elevation myocardial infarction evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol 2006 47(8) 1553. [Pg.323]

Three key features identifying high-risk patients with non- ST-segment-elevation ACS are a Thrombolysis in Myocardial Infarction (TIMI) risk score of 5 to 7, the presence of ST-segment depression on ECG, and positive CK MB or troponin. [Pg.291]

ACS = acute coronary syndrome CAD = coronary artery disease CHD = coronary heart disease DM = diabetes mellitus HTN = hypertension Ml = myocardial Infarction TIMI = Thrombolysis in Myocardial Infarction. [Pg.296]

Data regarding the acute benefit of /3-blockers in MI in the reperfusion era is derived mainly from the Thrombolysis in Myocardial Infarction (TIMI) II trial. In this trial, patients with ST-segment-elevation ACS were randomized to either IV metoprolol to be given as soon as possible following fibrinolytic administration followed by oral metoprolol or oral metoprolol deferred until day 6. Early administration of metoprolol was associated with a significant decrease in recurrent ischemia and early reinfarction. Patients receiving fibrinolytic therapy within 2 hours of symptom onset demonstrated the greatest benefit from early metoprolol administration. Based on the results of these trials, early administration of /8-blockers (to patients without contraindications) within the first 24 hours of hospital admission is a standard of quality patient care (see Table 16-3). [Pg.306]

TIME Thrombolysis in Myocardial Infarction TXA2 thromboxane A2... [Pg.315]

Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction Results of the Thrombolysis in Myocardial Infarction (TlMl) IIB study. Circulation 1991 83 422-437. [Pg.317]

TIMI-22 Thrombolysis in Myocardial Infarction Study 22 TLC Therapeutic lifestyle change... [Pg.450]

Antman EM, McCabe CH, Enrique P, et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial. Circulation 1999 100(15) 1593-601. [Pg.38]

Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998 98(25) 2805-14. [Pg.42]

Terrin ML, Williams DO, Kleiman NS, et al. Two- and three-year resultsofthe Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. J Ant Coll Cardiol 1993 22(7) 1763-72. [Pg.43]

See other pages where Thrombolysis in myocardial infarction is mentioned: [Pg.91]    [Pg.105]    [Pg.49]    [Pg.89]    [Pg.97]    [Pg.135]    [Pg.447]    [Pg.456]    [Pg.21]    [Pg.22]    [Pg.29]    [Pg.30]    [Pg.41]   


SEARCH



Infarct

Infarct, myocardial

Infarction

Myocardial infarction

Thrombolysis and angioplasty in myocardial infarction

Thrombolysis in Myocardial Infarction trial

© 2024 chempedia.info